Logo

ASTC

Astrotech Corporation

ASTC

Astrotech Corporation • NASDAQ
$3.21 ▼ -1.23% (-0.04)
Market Cap $5.38 M
52w High $8.15
52w Low $2.47
Dividend Yield 0%
P/E -0.38
Volume 2.22K
Outstanding Shares 1.68M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $297K ▲ $3.724M ▲ $-3.465M ▼ -1.167K% ▲ $-2.07 ▼ $-3.163M ▼
Q4-2025 $220K ▼ $2.661M ▼ $-2.93M ▲ -1.332K% ▼ $-1.76 ▲ $-2.597M ▲
Q3-2025 $534K ▲ $4.104M ▼ $-3.633M ▲ -680.337% ▲ $-2.18 ▲ $-3.35M ▲
Q2-2025 $261K ▲ $4.476M ▲ $-4.009M ▼ -1.536K% ▲ $-2.45 ▼ $-4.047M ▼
Q1-2025 $34K $3.637M $-3.278M -9.641K% $-2.01 $-3.36M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $13.936M ▼ $23.24M ▼ $4.153M ▼ $19.087M ▼
Q4-2025 $18.208M ▼ $26.989M ▼ $4.889M ▲ $22.1M ▼
Q3-2025 $20.869M ▼ $27.492M ▼ $2.74M ▼ $24.752M ▼
Q2-2025 $24.692M ▼ $31.001M ▼ $2.907M ▲ $28.094M ▼
Q1-2025 $28.308M $34.449M $2.388M $32.061M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-3.465M ▼ $-3.936M ▼ $3.518M ▲ $-36K ▼ $-454K ▼ $-4.384M ▼
Q4-2025 $-2.93M ▲ $-2.361M ▲ $2.677M ▼ $-28K ▲ $288K ▲ $-2.709M ▲
Q3-2025 $-3.633M ▲ $-3.861M ▼ $3.59M ▲ $-78K ▼ $-349K ▲ $-3.834M ▼
Q2-2025 $-4.009M ▼ $-3.044M ▲ $-279K ▼ $-34K ▲ $-3.357M ▲ $-3.363M ▲
Q1-2025 $-3.278M $-3.686M $-193K $-45K $-3.924M $-3.879M

Revenue by Products

Product Q2-2021Q3-2021Q4-2021Q1-2026
Grant
Grant
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲
Training
Training
 $0 ▲$0 ▲$0 ▲$0 ▲
Warranty
Warranty
 $0 ▲$0 ▲$0 ▲$0 ▲
First Detect Corporation
First Detect Corporation
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Astrotech looks more like a development-stage technology incubator than an operating industrial company. Over the past several years it has essentially reported no meaningful revenue and a steady pattern of operating losses. Those losses appear relatively small in absolute terms but are persistent and have not yet been offset by any proven, recurring sales base. Earnings per share are negative, which reflects both ongoing spending and the impact of multiple reverse stock splits over time. Overall, the income statement tells a story of a company still trying to turn promising technology into a real, scaled business.

Balance Sheet

Balance Sheet The balance sheet is very small and simple. Astrotech holds only a modest amount of assets, with cash representing the majority of what it owns and no financial debt on the books. Equity is positive but thin, which is typical for a micro‑cap, pre-commercial entity. The gradual decline in total assets and cash over recent years suggests the company has been funding its activities by drawing down its financial cushion, likely supplemented at times by issuing new shares rather than borrowing. In short, the balance sheet is clean but very light, underscoring the company’s limited financial resources.

Cash Flow

Cash Flow Cash flows show a steady outflow from operations with no offsetting inflows from a profitable business. The company consistently spends more cash than it brings in, reflecting ongoing R&D, product development, and overhead costs. There is essentially no capital spending, which means most cash burn is tied to people, labs, and commercialization efforts, not factories or heavy equipment. This pattern is typical for a small tech incubator but also means Astrotech depends on external financing or strategic transactions to sustain its activities over time.

Competitive Edge

Competitive Edge Astrotech’s competitive position is built around a specialized, miniaturized mass spectrometry platform originally rooted in space applications. This gives it a technically differentiated offering versus many traditional detection technologies, with advantages in sensitivity, portability, and speed. High scientific complexity, regulatory approvals, and patents create real barriers to entry. However, the company is tiny compared with large security, medical device, and industrial analytics players it ultimately competes against. Its success depends on winning certifications, contracts, and customer adoption in niche markets where its technology can clearly outperform incumbents, which is promising in theory but still not fully proven at commercial scale.

Innovation and R&D

Innovation and R&D Innovation is the company’s core strength. Astrotech uses its mass spectrometry platform as a base and spins out focused subsidiaries around it: 1st Detect for explosives and narcotics detection, AgLAB for cannabis and hemp processing optimization, BreathTech for breath-based disease screening, and newer efforts in environmental and process control testing. This “incubator” model allows the same core science to attack multiple markets, from airport security to medical diagnostics. The upside is significant if even one of these bets scales, especially BreathTech’s diagnostics and the TRACER 1000’s security applications, but regulatory approvals, clinical validation, and customer adoption are all uncertain and time‑consuming. R&D is clearly central to the story, but it has not yet translated into consistent, material revenue.

Summary

Astrotech is essentially a micro‑cap technology incubator built on a sophisticated scientific platform rather than a traditional aerospace and defense contractor with large, steady programs. Financially, it is pre‑revenue, loss‑making, and reliant on cash reserves and capital markets, with multiple reverse stock splits in its history pointing to long‑term shareholder dilution and volatility. Strategically, the portfolio of applications—security screening, cannabis processing, environmental testing, industrial control, and especially breath‑based disease diagnostics—offers meaningful potential if commercialization and regulatory milestones are achieved. At the same time, the company’s very small scale, ongoing cash burn, and early‑stage market positions create high uncertainty. The recently announced review of “strategic alternatives” adds another layer of unpredictability around its future structure and ownership, making Astrotech a story driven much more by technology execution and strategic outcomes than by current financial performance.

NEWS

November 19, 2025 · 9:15 AM UTC

Astrotech Announces Review of Strategic Alternatives to Maximize Shareholder Value

Read more

November 13, 2025 · 4:15 PM UTC

Astrotech Reports First Quarter of Fiscal Year 2026 Financial Results

Read more

October 31, 2025 · 4:15 PM UTC

Astrotech Corporation Appoints Scott Bartley as Interim Chief Financial Officer

Read more

September 25, 2025 · 4:35 PM UTC

Astrotech Reports Fiscal Year 2025 Financial Results

Read more